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Substantial progress has been made in the treatment of leukemia in childhood. Despite
this, leukemia remains a leading cause of pediatric cancer-related mortality and the prog-
nosis is guarded for individuals with relapsed or refractory disease. Standard therapies are
associated with a wide array of acute and long-term toxicities and further treatment inten-
sification may not be tolerable or beneficial. The curative potential of allogeneic stem cell
transplantation is due in part to the graft-versus-leukemia effect, which provides evidence
for the therapeutic capacity of immune-based therapies. In recent years there have been
significant advances in the development and application of immunotherapy in the treatment
of leukemias, including the demonstration of activity in chemotherapy-resistant cases.This
review summarizes immunotherapeutic approaches in the treatment of pediatric leukemia
including current results and future directions.
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INTRODUCTION
Leukemia is the most common form of cancer in childhood. Acute
lymphoblastic leukemia (ALL) accounts for approximately 75%
and acute myelogenous leukemia (AML) about 20% of pedi-
atric leukemia. Juvenile myelomonocytic leukemia (JMML) and
Philadelphia chromosome positive chronic myelogenous leukemia
(CML) are rare (Gloeckler et al., 1999). Despite great progress
in the development of curative therapies, leukemia remains one
of the most common causes of cancer-related mortality in pedi-
atrics (Kaspers and Creutzig,2005; Centers for Disease Control and
Prevention, 2007; Lange et al., 2008; Hunger et al., 2012). Addi-
tionally, current therapies are associated with a high-risk of acute
toxicities and long-term sequelae (Oeffinger et al., 2006; Arm-
strong et al., 2009; Diller et al., 2009). In recent years, there has
been significant progress in the development and application of
immunotherapy in the treatment of leukemias of childhood. Such
immune-based therapies have the potential to overcome resistance
to and decrease side effects of standard therapy. This review high-
lights immunotherapeutic approaches with applications in the
treatment of pediatric leukemia.
ALLOGENEIC STEM CELL TRANSPLANTATION AND THE
GRAFT-VERSUS -LEUKEMIA EFFECT: POTENT
IMMUNOTHERAPY IN THE TREATMENT OF CHILDHOOD
LEUKEMIA
Allogeneic hematopoietic stem cell transplantation (SCT) rep-
resents the most commonly employed and effective form of
immunotherapy for childhood leukemia. SCT can be curative
for all subtypes of pediatric leukemia and consensus guide-
lines for transplantation of acute leukemias have been published
(Oliansky et al., 2007, 2012a,b). The graft-versus-leukemia (GVL)
effect associated with allogeneic SCT is an immunologic reaction
mediated by donor lymphocytes against foreign antigens expressed
on leukemia cells. This GVL effect plays an important role in
leukemia-free survival after transplantation (Marmont et al., 1991;
Porter and Antin, 1999). Notably GVL may be linked with graft-
versus-host disease (GVHD), a frequent complication of SCT
caused by an immune reaction of donor cells against normal recip-
ient tissues. Accordingly, relapse rates after matched sibling donor
SCT are lower in individuals with AML and ALL who develop
GVHD in comparison to those without GVHD (Sullivan et al.,
1989; Horowitz et al., 1990). Furthermore, increasing the inten-
sity of GVHD prophylaxis can reduce the GVL effect leading to
a higher risk of relapse in children with acute leukemia. Conse-
quently, the approach to SCT in children and adolescents with
leukemia should attempt to balance the risks of GVHD with the
potential benefits of GVL.
Despite the effectiveness of SCT and GVL in the treatment
of leukemia, relapse remains the leading cause of treatment failure
after SCT (Pavletic et al., 2010) and outcomes after post-transplant
relapse are poor (Bajwa et al., 2012; Spyridonidis et al., 2012).
Novel approaches are needed to reduce the risk of post-transplant
relapse and to improve the outlook for individuals who relapse
after SCT (Bishop et al., 2010, 2012).
DONOR LYMPHOCYTE INFUSIONS FOR POST-TRANSPLANT RELAPSE
Donor lymphocytes infusions (DLI) can be curative for the treat-
ment of post-transplant relapse, which provides further evidence
of the potential of immunotherapy to cure leukemia. Complete
remission (CR) rates of 70% or higher are observed in the setting
of chronic phase CML, with lower rates (0–30%) in accelerated
and blastic phase CML, ALL, AML, and JMML (Collins et al., 1997;
Yoshimi et al., 2005; Tomblyn and Lazarus, 2008). Response rates
are highest in the setting of molecular or cytogenetic relapse. The
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optimal use of DLI for pediatric patients remains incompletely
defined. DLI are usually recommended for chronic phase CML,
although bcr/abl kinase inhibitors are also effective (Wright et al.,
2010). The results of DLI are poor for children with ALL and AML
(Porter et al., 2010).
LIMITATIONS OF THE GVL EFFECT
Despite the clear evidence that an allogeneic effect contributes
to the success of SCT for leukemia, as noted above, GVL is not
uniformly effective. For example, in contrast to myeloid cells, B-
lineage lymphoblasts often lack or have low-level expression of T
cell co-stimulatory molecules such that ALL blasts present anti-
gens poorly and may induce T cell anergy (Cardoso et al., 1996).
Another potential obstacle is the rapid proliferative rate of most
childhood leukemias, such that the tempo of progression may
outpace the kinetics of DLI-induced GVL. Consequently, novel
approaches to augment the GVL effect are needed. Additional
general limitations of SCT include the need for a suitable stem
cell donor, potential lack of donor availability for DLI (e.g., after
umbilical cord blood transplants), the risks of GVHD and other
causes of treatment-associated morbidity and mortality. For all of
these reasons, extensive efforts are underway to develop alternative
immunotherapeutic approaches.
ADOPTIVE CELL THERAPIES
The successes and the limitations of DLI in the management of
post-transplant leukemic relapse have spurred investigations of
other forms of adoptive cellular therapies, both in the allogeneic
and autologous settings.
LYMPHOCYTES
Cytotoxic T-lymphocytes (CTLs) have the ability to recognize tar-
get antigens on malignant cells. Notably, healthy stem cell donors
may have pre-existing leukemia-associated antigen-specific CTLs
that can expand in transplant recipients, which may contribute to
the eradication of leukemia after allogeneic transplantation (Rez-
vani et al., 2003). CTLs can be isolated from circulation, expanded
ex vivo and infused to treat cancer. Several leukemia-associated
antigen targets are being explored for CTL mediated therapy, for
example the Wilms tumor-1 (WT1) gene product (Doubrovina
et al., 2012a). WT1-specific T cells have been shown to correlate
with relapse-free survival in patients with hematologic malignan-
cies after allogeneic SCT (Rezvani et al., 2007). The use of CTLs
is not limited to treatment of leukemia relapse. CTLs specific to
Epstein–Barr virus (EBV), cytomegalovirus (CMV), and aden-
ovirus are currently under investigation to treat or prevent viral
reactivation (Leen et al., 2012) and EBV-lymphoproliferative dis-
orders (Rooney et al., 1998; Bollard et al., 2008; Doubrovina et al.,
2012b). CTLs directed against minor histocompatibility antigens
have been successfully used to treat relapsed leukemia after SCT in
adults (Falkenburg et al., 1999; Warren et al., 2010). There are also
strategies that can be employed to enhance lymphocyte effector
functions in general, for example, the ex vivo culture of lympho-
cyte subsets in specific conditions (Fowler and Gress, 2000; Porter
et al., 2006). Limitations of adoptive T cell therapies include the
need to identify target antigens with broad applicability, the poten-
tial requirement for human leukocyte antigen (HLA) matching,
“off-target” toxicities such as GVHD and the possible need for
long-term persistence of the transferred cells – all of which are
being addressed in ongoing investigations.
NATURAL KILLER CELLS
Natural killer (NK) cells are lymphocytes of the innate immune
system that can mediate a potent GVL effect early after SCT (Rug-
geri et al., 2008). Cytotoxicity is determined in part by mismatch
in the NK cell killer immunoglobulin-like receptor (KIR) types
between host and recipient, which are linked to the HLA system.
Thus, allogeneic donors can be selected for NK cell KIR mismatch.
A large number of clinical trials of allogeneic and autologous NK
cells are being conducted for individuals with active leukemia or
to augment GVL after SCT. NK cell cytotoxicity has been shown
to be potent against AML cells (Murphy et al., 2012). Accord-
ingly, the Children’s Oncology Group (COG) is conducting a trial
designed to assess the impact of NK cell KIR mismatch in the
setting of matched unrelated donor SCT for high-risk pediatric
AML (NCT00553202). A St. Jude Children’s Research Hospital
study of NK cells transduced with receptors to target CD19 is
being conducted for children with ALL (NCT00995137). Results
are pending. A clinical trial of donor-derived ex vivo activated NK
cells administered following SCT for children, adolescents, and
young adults with leukemias and solid tumors is in progress at the
National Cancer Institute (NCI) (NCT01287104).
CHIMERIC ANTIGEN RECEPTORS
T cells can be directed to target antigens on the surface of leukemia
blasts by introducing chimeric antigen receptors (CARs) through
gene therapy techniques. In general, the external domain of CAR
constructs consists of a monoclonal antibody variable fragment
(Fv), while the internal domains include components of the T cell
receptor signaling and often a co-stimulatory signaling domain.
CAR transduced cells are designed to enable immune effectors to
bind to and induce cellular cytotoxicity against malignant cells
that express target differentiation antigens (Cooper et al., 2003;
Rossig et al., 2005; Lee et al., 2012a). CARs recognize native
cell-surface antigens independently of antigen processing or HLA-
restricted peptide fragment presentation, which differs from CTL
based therapy. Most of the current CARs in testing utilize single
chain variable domains (ScFv) derived from a mouse monoclonal
antibody that binds to the target antigen, most commonly to
date, CD19 for the treatment of B-lineage hematologic malignan-
cies. The first generation CARs employed the CD3ζ cytoplasmic
domain to elicit T cell responses, but subsequent constructs also
include co-stimulatory molecules that serve to augment the T cell
response. Trials of T cells and NK cells engineered with CARs
directed to leukemia-targets are currently undergoing study in
children and adults with ALL and non-Hodgkin lymphoma (NHL)
at the Baylor College of Medicine (NCT00586391, NCT00608270,
NCT00840853), NCI (NCT01593696, NCT01087294), Children’s
Hospital of Philadelphia (CHOP) (NCT01029366), St. Jude Chil-
dren’s Research Hospital (NCT00995137), and the University Col-
lege, London (NCT01195480). Studies in adults demonstrate that
CAR-based therapy can lead to sustainable remissions with CAR
T cell expansion and persistence in the setting of chronic lympho-
cytic leukemia (CLL) and NHL (Kochenderfer et al., 2010, 2012;
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Porter et al., 2011). Early results in pediatric ALL are similarly
encouraging, including the induction of minimal residual disease
(MRD) negative CRs in cases of chemotherapy refractory disease
(Curran et al., 2012; Lee et al., 2012b; Porter et al., 2012). CARs
targeting other antigens such as CD22 and ROR1 in ALL (Baskar
et al., 2012; Dave et al., 2012; Haso et al., 2012) and CD33 in AML
(Dutour et al., 2012) are in development.
MONOCLONAL ANTIBODIES AND THEIR CONJUGATES
Since monoclonal antibodies (MoAbs) were first generated against
human differentiation antigens there has been the expectation that
they would be used to treat hematologic malignancies (Kohler and
Milstein, 1975). Myeloid and lymphoid leukemias are excellent
candidates for MoAb-based therapies as they demonstrate sur-
face expression of multiple human differentiation antigens that
are rarely, if ever, found on other normal tissues and are gener-
ally accessible in the circulation. Importantly, due to the severe
immunosuppression that is commonly associated with leukemia
and its treatment, the incidence of anti-drug antibody formation
(e.g., human anti-murine antibodies, anti-toxin antibodies) may
be reduced. Advances in antibody engineering have led to the
production of MoAbs and their fragments for clinical use and to
generate humanized chimeric constructs to reduce their immuno-
genicity. Multiple reagents that target leukemia-associated surface
antigens have been developed for clinical investigation (Table 1),
some of which have applications in pediatric leukemia.
UNCONJUGATED MONOCLONAL ANTIBODIES
Unconjugated MoAbs have the potential to kill cells by direct
and/or indirect mechanisms. Examples of direct effects include
blockade of receptor/ligand interactions with interruption of
growth signals, agonistic binding, and induction of apoptosis
through initiation of a death-signal. Indirect killing is com-
monly immune-mediated, via complement-dependent cytotoxic-
ity (CDC) and antibody-dependent cellular cytotoxicity (ADCC).
In CDC, the Fc receptor of the MoAb fixes the complement
protein C1q and triggers cell death by the activation of the com-
plement cascade. ADCC is mediated by Fc interaction with and
activation of effector cells such as NK cells and macrophages.
Importantly, ADCC requires functional immune effector mecha-
nisms, which may be deficient in the setting of childhood leukemia
(Haining et al., 2005). It is likely that unconjugated MoAbs will
have limited single agent efficacy in most cases of childhood
leukemia, (Raetz et al., 2008a) although occasional CRs have been
reported with MoAbs targeting CD52 (alemtuzumab) (Laporte
et al., 2004), CD20 (rituximab) (Corbacioglu et al., 2003), and
CD33 (lintuzumab) (Feldman et al., 2003). Additionally, activity
was observed in some children with newly diagnosed mature B-
cell ALL and NHL treated with single agent rituximab in a Phase
II window study (Meinhardt et al., 2010).
Monoclonal antibodies have the potential to sensitize malig-
nant cells to chemotherapy and/or radiotherapy (Wilson et al.,
2009) or to induce the cell-surface expression of additional anti-
gen targets (Rubinfeld et al., 2006), thus providing a rationale for
combination therapy. Increased CD20 expression on ALL blasts
has been observed during induction and corticosteroid therapy,
which may make anti-CD20 directed therapy more effective fol-
lowing standard treatment (Dworzak et al., 2008). There is also
the rationale for utilizing MoAbs in combination with adoptive
cell therapies, for example to augment ADCC (Lang et al., 2004).
Table 1 | Monoclonal antibodies and conjugates.
Antigen Unconjugated monoclonal antibodies Conjugates
CD2, CD3 Antithymocytes globulin, OKT3, siplizumab, UCHT1 Pokeweed antiviral protein, saporin, ricin-dgA, diphtheria
toxin A, TRAIL
CD19 MDX-1342, BU-12 Maytansinoid DM4, liposomal doxorubicin, pokeweed
antiviral protein, ricin-dgA, ricin-blocked saporin, 131I, 90Y
CD19 and CD3 (bi-specific) Blinatumomab –
CD20 Rituximab, ofatumumab Calicheamicin, 131I, 111In, 90Y
CD19 and CD22 – Combotox, Ricin-dgA
CD22 Epratuzumab Moxetumomab pasudotox (PE38), Ricin-dgA, Inotuzumab
ozogamicin (calicheamicin), 131I, 186Re, 90Y
CD25 Daclizumab PE38, ricin-dgA, 90Y
CD25/CD122/CD132 – Diptheria toxin A&B (Denileukin diftitox)
CD33 Lintuzumab Gemtuzumab ozogamicin (calicheamicin), maytansinoid
DM4, 131I, 213Bi, 90Y
CD45 Anti-CD45 131I
CD52 Alemtuzumab –
dgA, deglycosylated ricin A chain; PE, pseudomonas exotoxin A modified; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.
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Based on the efficacy of unconjugated anti-CD20 MoAb (rit-
uximab) in combination with chemotherapy for adults with NHL
(Coiffier et al., 2002), studies have been designed to incorpo-
rate this agent into leukemia treatment. A trial conducted by
investigators at the MD Anderson Cancer Center suggests that rit-
uximab can be safely administered with the Hyper-CVAD regimen
(cyclophosphamide, vincristine, adriamycin, and dexamethasone)
and that adults with B-ALL might have improved leukemia-free
survival in comparison to chemotherapy-only historical controls
(Thomas et al., 2006, 2010). Results of a recent COG trial indicate
that rituximab can be added to ifosfamide, carboplatin, and etopo-
side chemotherapy with an acceptable toxicity profile (Griffin
et al., 2009). A pediatric trial of rituximab with chemotherapy for
individuals with newly diagnosed B-ALL was recently completed
through the COG (NCT00057811) with results pending.
Ofatumumab, is a fully humanized anti-CD20 MoAb that binds
to a different epitope than rituximab and has stronger CDC activ-
ity in pre-clinical studies. A Phase II study of the Hyper-CVAD
regimen in combination with ofatumumab as frontline therapy
for patients with CD20 positive ALL is currently being conducted
by investigators at MD Anderson Cancer Center (NCT01363128).
A study of the anti-CD22 MoAb epratuzumab in combination
with standard chemotherapy was recently completed through the
COG (NCT00098839). This trial included an initial cohort with
an upfront epratuzumab monotherapy phase (Raetz et al., 2008a).
The clinical activity of epratuzumab as a single agent was limited,
with no complete or partial remissions observed in 15 patients,
however it was well tolerated, both as a single agent and in combi-
nation with chemotherapy. In comparison to historical experience
with the same chemotherapy backbone (Raetz et al., 2008b), the
percentage of those individuals in CR after one block of induction
who were MRD negative appeared favorable (Raetz et al., 2011).
CONJUGATED MONOCLONAL ANTIBODIES
The cytotoxicity of MoAbs can be increased by linkage to toxic
moieties including chemotherapeutic agents, toxins, and radionu-
clides. Monoclonal antibody-based therapeutic agents armed with
such potently cytotoxic compounds do not require active immune
response mechanisms for activity and thus can be effective even in
profoundly immunocompromised hosts.
Chemotherapeutic conjugates
Monoclonal antibodies have been conjugated to various active
chemotherapy drugs. The first such agent to receive FDA approval
was gemtuzumab ozogamicin (Mylotarg), which is an anti-CD33
MoAb linked to calicheamicin, a potent antitumor antibiotic. Clin-
ical trials of gemtuzumab ozogamicin as a single agent and in com-
bination with chemotherapy have been conducted in the setting of
pediatric AML (Arceci et al., 2005; Aplenc et al., 2008). Approxi-
mately 30% of pediatric patients with relapsed and refractory AML
respond to gemtuzumab ozogamicin as a single agent. Phase III
trials designed to assess the efficacy of gemtuzumab ozogamicin in
combination with chemotherapy in pediatric AML was initiated
by the COG (AAML0531) with preliminary results suggestive of
safety and efficacy in a pilot trial (Franklin et al., 2008). However,
gemtuzumab ozogamicin was voluntarily withdrawn by its man-
ufacturer in 2010 at the request of the FDA. This withdrawal was
based on results of a randomized Phase III trial designed to assess
the efficacy of gemtuzumab ozogamicin in combination with stan-
dard chemotherapy for adults with de novo AML conducted by the
Southwest Oncology Group. There was no demonstrated benefit
and increased rates of veno-occlusive disease and fatal toxicity
were observed in the gemtuzumab ozogamicin arm (Petersdorf
et al., 2013). Accrual to the COG AAML0531 trial was discontinued
in 2010 when gemtuzumab ozogamicin was no longer available.
Final analysis of results in those patients who had completed ran-
domized therapy awaits longer follow-up. The Nordic Society of
Paediatric Haematology and Oncology (NOPHO) conducted a
randomized Phase III study of gemtuzumab ozogamicin as con-
solidation in children with AML (Hasle et al., 2012). There was no
impact on the rate of relapse or survival in this study. A random-
ized, Phase III open-label study that employed fractionated low
doses of gemtuzumab ozogamicin for adults with de novo AML
(ALFA-0701) demonstrated improved event-free, relapse-free, and
overall survival rates without an increase in fatal toxicity, suggest-
ing that perhaps lower and fractionated dosing of this novel agent
may be effective and more tolerable than previously tested regi-
mens (Castaigne et al., 2012). Gemtuzumab ozogamicin has also
been used to treat occasional cases of ALL with CD33 expression,
with anecdotal reports of successful remission induction (Zwaan
et al., 2003).
Inotuzumab ozogamicin is a CD22-targeted antibody conju-
gated to calicheamicin. A CR rate of 57% was observed in a Phase
II trial in adults with relapsed and refractory ALL (Kantarjian et al.,
2012). A randomized Phase III trial in adults (NCT01564784) is
ongoing and a pediatric Phase I trial is planned.
Toxin conjugates
Bacterial and plant toxins such as Diphtheria, Pseudomonas, and
ricin are highly potent cellular poisons. In addition, toxins are
not susceptible to the multiple drug resistance gene-mediated
mechanism of resistance to chemotherapy (Pastan et al., 2006).
Immunotoxins are engineered proteins that consist of a MoAb-
based targeting moiety linked to a toxin that upon internalization
induces cell death by inhibiting protein synthesis. In general,
clinical development of immunotoxins has been hindered by
non-specific toxicities, immunogenicity, and production difficul-
ties. At the NCI, a 38 kDa truncated derivative of Pseudomonas
exotoxin A (PE38) has been used in the development of recom-
binant immunotoxins that target human differentiation antigens
(FitzGerald et al., 2011). Serial modifications have reduced non-
specific toxicities, increased stability, increased tissue penetration,
and improved targeted cytotoxicity.
Recombinant anti-CD22 immunotoxins that contain the vari-
able domains of the anti-CD22 MoAb RFB4 fused to a 38 kDa
fragment of PE38 have been developed and tested at the NCI (Pas-
tan et al., 2006). The first generation agent, BL22 (CAT-3888), was
shown to be highly active in a Phase I study in adults with B-
lymphoid malignancies (Kreitman et al., 2005, 2009, 2012). In a
pediatric Phase I trial conducted at the NCI, BL22 had an accept-
able toxicity profile and activity was seen at all dose levels (Wayne
et al., 2010). A Phase I trial of a second-generation agent, moxetu-
momab pasudotox (HA22, CAT-8015), with higher CD22 binding
affinity and increased pre-clinical activity (Mussai et al., 2010) is in
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progress (NCT00659425) with early results demonstrating CRs in
children with chemotherapy refractory ALL (Wayne et al., 2011).
Phase II trials of this agent are in development. Additionally, syn-
ergistic cytotoxicity was seen when moxetumomab pasudotox was
combined with standard chemotherapy agents in pre-clinical stud-
ies (Ahuja et al., 2007) and a combination trial for pediatric ALL
is planned.
Pediatric phase I trials of anti-CD19 immunotoxins have also
been conducted (Uckun et al., 1999; Dinndorf et al., 2001), but
these agents have not moved forward in clinical development. A
Phase I trial of an immunotoxin mixture that targets CD19 and
CD22 (Combotox) was performed in children with ALL with a
reported CR rate of 21% (3 of 14 evaluable patients) (Herrera
et al., 2009). Similar results were seen in a Phase I study in adults
with ALL where a CR rate of 18% (3 of 17 subjects) and dose-
limiting vascular-leak syndrome were observed (Schindler et al.,
2011).
Radioimmunoconjugates
Monoclonal antibodies that target leukemia-associated or
hematopoietic lineage antigens have been linked to radioactive
isotopes, most commonly β-emitters (e.g., 90Yttrium, 131Iodine,
186Rhenium) and less frequently α-emitters (e.g., 213Bismuth)
(Table 1). As these agents are concentrated in the marrow,
they are associated with severe myelosuppression. Consequently,
radioimmunotherapy has limited application in leukemia except
as part of SCT regimens. 131Iodine conjugated-anti-CD45 MoAb
in combination with non-myeloablative pre-transplant condi-
tioning appeared to improve engraftment without a significant
increase in toxicity in adults with advanced AML and high-risk
myelodysplastic syndromes (Pagel et al., 2009). There have been
very few pediatric trials of radioimmunoconjugates at least in part
due to concerns for late effects of radiation.
Other conjugates
Other MoAb-based approaches have been employed to target
leukemia-associated antigens. For example, anti-CD7 has been
conjugated to tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) fusion protein, which has potential utility in
T-ALL (Bremer et al., 2005).
Bi-SPECIFIC MONOCLONAL ANTIBODIES
Bi-specific antibodies have been designed to target both a
leukemia-associated antigen and a surface receptor on immune
effector cells such as T cells. The anti-CD19/anti-CD3ε bi-specific
antibody (MT103, blinatumomab) is undergoing clinical devel-
opment for the treatment of B-lineage hematologic malignancies
in children and adults. In a Phase II trial for adults with ALL
in MRD+ CR, this agent induced clearance of MRD and a high
relapse-free survival rate in most patients (Topp et al., 2011,
2012a). In a subsequent exploratory phase II trial, blinatumomab
was shown to induce CRs in adults with relapsed/refractory ALL
(Topp et al., 2012b). A pediatric Phase I/II trial is currently in
progress (NCT01471782). Importantly, bi-specific MoAbs require
functional immune effector cells (e.g., T cells) for activity. Thus,
it is possible that these agents may have increased activity follow-
ing immune reconstitution after allogeneic SCT. Notably in that
regard, three children with post-transplant relapse of ALL suc-
cessfully achieved CRs with blinatumomab (Handgretinger et al.,
2011).
CANCER VACCINES
Initial studies of autologous cancer vaccines have been conducted
in adult subjects. Subsequently, studies have been initiated in
pediatric populations as well in the allogeneic setting.
THE IMMUNE RESPONSE
T cells recognize antigens as small digested peptides displayed on
the surface of antigen presenting cells (APCs) in the context of
HLA. The generation of a successful T cell response requires the
interaction of an appropriate T cell receptor with its cognate anti-
gen/HLA complex as well as co-stimulation or a “second signal.”
This second signal can be supplied in the form of an appropri-
ate cytokine or by direct cell-to-cell interaction through accessory
molecules.
LEUKEMIA-ASSOCIATED ANTIGENS
Numerous leukemia-associated antigens capable of inducing a
T cell mediated immune response have been targeted with can-
cer vaccines. Examples include translocation fusion products,
lineage-specific antigens, genes that are expressed aberrantly or in
higher than normal levels, histocompatibility antigens and viral-
associated antigens expressed by malignant cells. Various antigen
sources have been used in vaccine trials. Peptides with defined
sequences can be readily synthesized for clinical use and these
have been employed most commonly.
PEPTIDE AND FULL-LENGTH mRNA VACCINES
Immunologic, clinical, and/or molecular responses have been
observed in adults with leukemia treated with peptide vaccines tar-
geting PR1 (Rezvani et al., 2008), WT1 (Mailander et al., 2004; Oka
et al., 2004), and the bcr/abl breakpoint peptide (Jain et al., 2009).
Importantly, the applicability of a peptide vaccine is restricted
by both the specific antigen epitope and the HLA binding motif.
Full-length mRNA vaccines represent a strategy to overcome such
HLA and epitope restrictions. A clinical trial of a full-length WT1
mRNA dendritic cell vaccine in adults with AML demonstrated
the potential utility of this approach in eliciting both clinical and
immunological responses (Van Tendeloo et al., 2010).
DENDRITIC CELL-BASED VACCINES AND ARTIFICIAL ANTIGEN
PRESENTING CELLS
Dendritic cells are professional APCs that can be readily gener-
ated from peripheral blood monocytes and employed in cancer
vaccines (Wong et al., 2001). Artificial APCs that express co-
stimulatory molecules have also been engineered for use in cancer
immunotherapy trials (Suhoski et al., 2007). Peptides, nucleic
acids, proteins, and tumor lysates can be used to prime APCs to
present leukemia-associated antigens. A clinical trial of a WT1
peptide allogeneic dendritic cell vaccine is being conducted at
the NCI for children and adults with WT1-expressing hemato-
logic malignancies and persistent or relapsed disease after SCT
(NCT00608166). In this study, vaccines are administered along
with DLI in attempt to augment the GVL effect, and immune
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responses have been observed in children with ALL treated on this
trial (Shah et al., 2011).
WHOLE TUMOR CELL VACCINES
Autologous and allogeneic tumor cell preparations can be
employed as immunogenic sources in cancer vaccines in order to
obviate the need to define the target antigen(s) and to avoid spe-
cific HLA allele restriction. The ready access to peripheral blood or
bone marrow blasts makes this particularly applicable for leukemia
vaccine trials. Blasts from children with B-precursor ALL can be
rendered capable of presenting antigens by incubation with CD40
ligand and interleukin-4, thus, overcoming their ability to induce
T cell anergy (Cardoso et al., 1996). However, a clinical trial using
that approach was unsuccessful possibly due to both rapid disease
progression and severe underlying immunosuppression (Haining
et al., 2005).
ADJUVANTS AND COMBINATIONS
The optimal immunotherapy reagents and regimens are expected
to vary between diseases and individual cases. Critically impor-
tant is the need to overcome the immune deficits associated with
childhood leukemia and its treatment (Haining et al., 2005). Con-
sequently, adjuvants are commonly employed to potentiate an
immune response as part of immunotherapy trials (e.g., Mon-
tanide, GM-CSF, keyhole limpet hemocyanin). Toll-like receptors
(TLRs) are a family of immune receptors that recognize struc-
turally conserved molecules derived from microbes. TLR agonists
can stimulate both innate and adaptive immune responses and
have shown pre-clinical activity against ALL (Fujii et al., 2007). A
pediatric Phase I trial of a TLR agonist for ALL and AML is in
progress (NCT01743807).
CONCLUSION
Although great strides have been made in the curative treat-
ment of childhood leukemias, further progress will require novel
therapeutic approaches (Wayne et al., 2008). Immunotherapy
has the potential to mediate anti-leukemia activity with lim-
ited non-specific toxicities. As with chemotherapy, however, each
immunotherapeutic approach has its own set of limitations,
applicability, and risks and no single approach will be sufficient
to treat all patients. Systematic study of multiple immune-based
therapies will be necessary in order to define the optimal regimens
and uses in the ongoing effort to develop new treatments for chil-
dren, adolescents, and young adults with leukemia. Based on the
potency of the GVL effect after SCT, it is predicted that methods
that can induce and/or augment anti-leukemia immune responses
hold great promise in the treatment of pediatric leukemia.
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